The use of PDE4 inhibitors as a therapeutic approach for inflammatory disorders has been validated by treating conditions such as neuroinflammation, RA, lupus, inflammatory bowel disease, asthma, dermatitis, psoriasis, atopic conditions, and chronic obstructive pulmonary disease
It also modulates the activity of matrix metalloproteinases (MMPs) and their inhibitors, supporting balanced collagen remodeling rather than excessive breakdown or fibrosis
Telehealth-only: Yes online evaluation, physician-supervised protocols Menu: BPC-157 (Wolverine), MOTS-c, GHK-Cu, CJC-1295/Ipamorelin, Tesamorelin, Glutathione, NAD+, Retatrutide & more Insurance: Not accepted
In addition, ROS-responsive curcumin-loaded nanoparticle systems (NPSBG@Cur) have been shown to activate autophagy while dynamically limiting lipid accumulation in AKI